Skip to main content
Advertisement
Advertisement
SCYX
SCYX logo
SCYNEXIS, Inc.
3.50
USD
Sponsored
+0.20
+6.06%
Nov 06, 15:59 UTC -5
Closed
exchange

After-Market

3.51

+0.01
+0.29%

SCYNEXIS, Inc. (SCYX) Earnings

SCYX Earnings Reports

Positive Surprise Ratio

SCYX beat 31 of 43 last estimates.

72%

Next Report

Next Week
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$88.74K
/
-$0.62
Implied change from Q2 26 (Revenue/ EPS)
-62.24%
/
-198.41%
Implied change from Q3 25 (Revenue/ EPS)
-73.43%
/
-54.41%

SCYNEXIS, Inc. earnings per share and revenue

On Aug 10, 2026, SCYX reported earnings of 0.63 USD per share (EPS) for Q2 26, beating the estimate of -0.51 USD, resulting in a 221.90% surprise. Revenue reached 235.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a -6.21% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.62 USD, with revenue projected to reach 88.74 thousand USD, implying an decrease of -198.41% EPS, and decrease of -62.24% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
logo
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
logo
Guardian Pharmacy Services, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.30
Actual
$0.33
Surprise
+7.84%
logo
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.02
Actual
$0.06
Surprise
+144.90%
logo
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
logo
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.89
Actual
$1.96
Surprise
+3.17%
logo
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.32
Actual
$0.36
Surprise
+9.16%
logo
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.36
Surprise
-11.15%
logo
Profound Medical Corp. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.18
Actual
-$0.21
Surprise
-11.41%
logo
Akebia Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.03
Actual
-$0.04
Surprise
-6.95%
FAQ
For Q2 2026, SCYNEXIS, Inc. reported EPS of $0.63, beating estimates by 221.9%, and revenue of $235.00K, 0% as expectations.
The stock price moved down -6.21%, changed from $5.16 before the earnings release to $4.83 the day after.
The next earning report is scheduled for Nov 11, 2026.
Based on 3 analysts, SCYNEXIS, Inc. is expected to report EPS of -$0.62 and revenue of $88.74K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement